Navigation Links
Excipients Help Pharma Extend Product Life, Profits

NEW YORK, April 2, 2008 /PRNewswire/ -- With their ability to extend product life, excipients are being turned to increasingly as part of Big Pharma's strategy during lean times, and this portends a robust market for them, according to a new report from a major life sciences market research publisher. There are about 1200 excipients on the market, used in all types of pharmaceuticals. This $4.6 billion market has witnessed healthy growth in the past few years and is expected to continue along the same trajectory through 2012, due to increased demand from new drug targets, new biological drugs, new formulations and synthetic agents, according to Kalorama Information's new report Pharmaceutical Excipients for Oral Formulations, 2nd Edition.

Pharmaceutical excipients are substances, other than the pharmacologically active drug or prodrug, which are included in the manufacturing process or are contained in the finished pharmaceutical product dosage form. Excipients provide enhanced functionality to pharmaceuticals, aid in drug development and innovation and help improve patent life, all at a lower cost.

The pharmaceutical industry continues to be weighed down by the pressure to cut costs, by generic competition, and a lack of innovation. In this environment, excipients are becoming a more important aspect in tablet manufacture than they were previously and are even helping to develop innovative drug formulations. For example, innovations in delivery, such as sustained release, allow pharmaceutical companies to extend the patent life on existing products.

"Once they were thought of as fillers, but today the line between active ingredients and excipients has blurred," notes Bruce Carlson, publisher of Kalorama Information. "As companies need to develop cost-cutting strategies, excipients are now thought of as functional materials rather than inactive bulking agents."

Kalorama Information's report Pharmaceutical Excipients for Oral Formulations, 2nd Edition covers five key segments, including binders/fillers, coating agents, disintegrants, lubricants and sweeteners. Profiles of leading excipient producers are included. The information presented is the result of primary research interviews conducted with industry executives, as well as data gathered through secondary research. The report can be purchased directly from Kalorama Information by visiting

About Kalorama Information

Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. For more information, contact Andrea Hiller at 212-807-2673 or, or visit

SOURCE Kalorama Information
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
5. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
Post Your Comments:
(Date:6/23/2016)... June 23, 2016 Houston Methodist Willowbrook ... Cy-Fair Sports Association to serve as their official ... Houston Methodist Willowbrook will provide sponsorship support, athletic ... with association coaches, volunteers, athletes and families. ... Cy-Fair Sports Association and to bring Houston Methodist ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... the Pennsylvania Convention Center and will showcase its product’s latest features from June ... be presenting a scientific poster on Disrupting Clinical Trials in The Cloud during ...
Breaking Biology Technology:
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:4/13/2016)... 13, 2016  IMPOWER physicians supporting Medicaid patients in ... new clinical standard in telehealth thanks to a new ... higi platform, IMPOWER patients can routinely track key health ... mass index, and, when they opt in, share them ... to a local retail location at no cost. By ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
Breaking Biology News(10 mins):